ImmunityBio Inc (NASDAQ:IBRX) price on current trading day, rose 7.44% above its previous day’s close as an upside momentum from buyers pushed the stock’s value to $2.60.
A look at the stock’s price movement, the close in the last trading session was $2.42, moving within a range at $2.3501 and $2.735. The beta value (5-Year monthly) was -0.127. Turning to its 52-week performance, $10.53 and $2.28 were the 52-week high and 52-week low respectively. Overall, IBRX moved -7.80% over the past month.
ImmunityBio Inc’s market cap currently stands at around $2.22 billion, with investors looking forward to this quarter’s earnings report slated for on 2025-Mar-02.
Analysts have a consensus estimate of 17.5M for the company’s revenue for the quarter, with a low and high estimate of 13.78M and 19.74M respectively. The average forecast suggests up to a 43,644.38% growth in sales growth compared to quarterly growth in the same period last fiscal year. Wall Street analysts have also projected the company’s year-on-year revenue to grow to 105.24M, representing a 613.74% jump on that reported in the last financial year.
Turning to the stock’s technical picture we see that short term indicators suggest on average that IBRX is a 100% Sell. On the other hand, the stock is on average a 100% Sell as suggested by medium term indicators while long term indicators are putting the stock in 100% Sell category.
1 analyst(s) have given their forecast ratings for the stock on a scale of 1.00-5.00 for a strong buy to strong sell recommendation. A total of 0 analyst(s) rate the stock as a Hold, 0 recommend IBRX as a Buy and 0 give it an Overweight rating. Meanwhile, 0 analyst(s) rate the stock as Underweight and 1 say it is a Sell. As such, the average rating for the stock is Sell which could provide an opportunity for investors keen on increasing their holdings of the company’s stock.
IBRX’s current price about -9.00% and -15.28% off the 20-day and 50-day simple moving averages respectively. The Relative Strength Index (RSI, 14) currently prints 42.04, while 7-day volatility ratio is 12.66% and 9.03% in the 30-day chart. Further, ImmunityBio Inc (IBRX) has a beta value of 0.35, and an average true range (ATR) of 0.28. Analysts have given the company’s stock an average 52-week price target of $6, forecast between a low of $6 and high of $6. Looking at the price targets, the low is -130.77% off current price level while to achieve the yearly target high, price needs to move -130.77%. Nonetheless, investors will most likely welcome a -130.77% jump to $6 which is the analysts’ median price.
If we refocus on ImmunityBio Inc (NASDAQ:IBRX), historical trading data shows that trading volumes averaged 9.08 over the past 10 days and 6.50 million over the past 3 months. The company’s latest data on shares outstanding shows there are 852.74 million shares.
The 89.60% of ImmunityBio Inc’s shares are in the hands of company insiders while institutional holders own 9.91% of the company’s shares. Also important is the data on short interest which shows that short shares stood at 59.54 million on 2025-03-14, giving us a short ratio of 9.03. The data shows that as of 2025-03-14 short interest in ImmunityBio Inc (IBRX) stood at 1870.9999999999998 of shares outstanding, with shares short rising to 56.96 million registered in 2025-02-14. Current price change has pushed the stock 1.56% YTD, which shows the potential for further growth is there. It is this reason that could see investor optimism for the IBRX stock continues to rise going into the next quarter.
